1

The History of ZIKV Discovery

1.1   ZIKV Isolation from Monkeys and Mosquitos

Zika virus (ZIKV) was first isolated in April 1947 in a forest named "Ziika" near Lake Victoria in Uganda (1, 2). It is interesting to note that the term *Ziika* means "overgrowth" in Luganda (the Bantu language of the Baganda people, commonly used in Uganda). The virus was isolated by researchers from The National Institute for Medical Research in London, United Kingdom (G. W. A. Dick), and The Rockefeller Foundation in New York, United States (S. F. Kitchen and A. J. Haddow), as part of collaborative studies with the Yellow Fever Research Institute in Entebbe, Uganda (Figure 1.1) (1, 2).

To monitor emerging infections, the investigators commenced studying the sentinel rhesus monkeys in Bwamba, Uganda, in 1946 (Figure 1.2) (1). Zika Forest was chosen because it was well-known that monkeys in that area had a high immunity to yellow fever virus (YFV) (3–6). Most of the forest was parallel to the Entebbe-Kampala Road, and the monkeys were kept in cages in the canopy of the trees (1, 7–9).

At that time, six monkey rhesus (MR) were monitored daily for any variation in their body temperature. One of the monkeys, named MR766, presented an increase in temperature on April 18; hence, a blood sample was collected on April 20. MR766 was monitored for more 30 days but no other symptom was detected. The blood sample collected from MR766 was injected subcutaneously (S.C.) into another monkey named MR771, and into Swiss albino mice, intracerebrally (I.C.) and intraperitoneally (I.P.), for further studies. No sign of

Figure 1.1 Alexander J. Haddow in the Zika Forest. The base of the platform used to capture mosquitoes and keep the monkeys can be observed. Obtained from the University of Glasgow (AJ Haddow and University of Glasgow Archives & Special Collections, Papers of AJ Haddow, GB248 DC 068/80/63).

infection was observed in either MR771 or the mice injected by I.P. for up to 30 days after inoculation. However, the mice injected by I.C. became sick 10 days post-infection (d.p.i.), and the first ZIKV isolation was obtained from these animals. Since this virus was neutralized by serum taken from monkeys MR766 (on May 20) and MR771 (at 35 d.p.i.) but not by sera from these same monkeys before their exposure to ZIKV, the researchers proved that the virus isolated from the mice was originated from monkey MR766. For this reason, the first ZIKV strain isolated was named MR766. A neutralizing antibody is the antibody that can protect the cells from an infection by neutralizing its biological effect (in this case, infection). In this study, it was used in an assay to determine if the virus detected in one animal was the same as the one isolated from the previous animal (1).

In addition to analyzing and collecting samples from the monkeys, the researches were collecting mosquitos for the YF studies (Figure 1.3). *Aedes africanus* were among the captured ones in 1948. This mosquito was suspected to be involved in the YFV cycle at that time. From January 5 to January 20, nine lots of mosquitos were

Figure 1.2 Details of the steel tower used as a platform to collect mosquitos, and to keep the caged monkeys in the Zika Forest. The platforms can reach the canopy of the trees. Obtained from the University of Glasgow (AJ Haddow and University of Glasgow Archives & Special Collections, Papers of AJ Haddow, GB248 DC 068/80/62).

acquired, and their samples were processed and injected into mice by I.C. with both unfiltered supernatants and Seitz E.K. filtrates. The second isolation of ZIKV (strain E/1), which was also the first from mosquitos, was from lot E/1/48, captured on January 11−12, with 86 mosquitos (1). All six mice inoculated with the unfiltered sample were inactive at 7 d.p.i. For animals that received the filtrated sample, one died at 6 d.p.i. while other was sick at 14 d.p.i.

Figure 1.3 Details on the stairs used to access and recover the mosquitoes caught. A boy can be observed in the picture, since they were used to help the researchers to collect the samples in the high height. Obtained from the University of Glasgow (AJ Haddow and University of Glasgow Archives & Special Collections, Papers of AJ Haddow, GB248 DC 068/80/49).

Those inoculates were also injected S.C. into MR758, which showed no sign of sickness. Based on the results observed with the sick mice, blood samples from MR758 were collected on the 8th, 9th, and 10th d.p.i., which were I.C. injected into six mice. From the first injection, one mouse died at 10 d.p.i. and another two became sick at 19 and 20 d.p.i. From the second group of injection, one died at 13 d.p.i., one was sick at 12 d.p.i., and another one developed paralysis, which was identified

as Theiler's encephalomyelitis (10, 11). Mice injected with samples from the third collection had no symptom. Neutralization tests with serum from MR758 proved that these animals had developed neutralization antibodies to ZIKV strains E/1 and MR766. It was concluded that ZIKV was identical to neither YFV, Dengue virus (DENV), nor Theiler's mouse encephalomyelitis virus (TMEV) (1).

Dick (1952) observed that the virus isolated from MR766 and mosquitos was well adapted after 90 passages in the mouse brain. Data from studies analyzing adaption and pathogenesis became more reproducible. Among the three ZIKV strains tested (MR766, MR758, and E/1), the virus from MR758 caused more cases of mice that presented with paralysis in early passage than the virus from MR766. With all the strains evaluated, the first sign of infection was roughness of the coat. Infection by I.P. injection in mice older than 2 weeks of age was not as efficient in those of 7 days old. Using a late-passage virus, no significant difference in the infection was observed between unweaned and 5- to 6-week-old mice (2).

The virus tropism was examined by analyzing infection in different organs, including brain, kidney, lung, liver, and spleen. The results of the mice inoculated by I.C. indicated that the brain was the main target of ZIKV. While other animals including cotton-rat and guinea pigs could also be infected with ZIKV, no symptom was observed. On the other hand, rabbits could produce antibodies by 21 d.p.i. Other species of monkeys—including rhesus (6 animals), grivet (13 animals), and redtails (2 animals)—were also infected and analyzed. Circulating antibodies were detected in Grivet 733 and Redtail 1044 after ZIKV infection. Interestingly, Grivet 1019 was naturally infected by ZIKV, but this monkey was captured in Sese Island, which was not in the Zika region. In 1950, among the monkey rhesus used for the YFV research, animal MR801 was naturally positive for ZIKV but the only symptom was minor pyrexia. MR801 was kept in the same platform (number 3) where the strain E/1 was isolated from the captured mosquitoes. Platform number 3 was 0.2 miles from platform number 5 where MR766 was infected (2). Antibodies against ZIKV were not detected in small mammals that were trapped in the forest, indicating that the infection was restricted to monkeys, mosquitos, and human beings at that time (12, 13).

Other ZIKV strains were isolated in 1958 from two different catches of *Aedes africanus*, consisting of 206 (strain Lunyo V) and 127 (strain Lunyo VI) mosquitoes. The Lunyo V strain caused viral encephalitis,

skeletal myositis, and myocarditis in adults and infant mice. The virus was passed through the brain and the heart into infant mice via I.C. or I.P. injections. Some of the mice injected with Lunyo VI were paralyzed. The strains were injected into monkeys MR1059 and MR1063, respectively, and no symptoms of infection were observed (14). ZIKV was further isolated from *Aedes luteocephalus* in Nigeria (15).

1.2 ZIKV Infection in Humans

The timing of the first ZIKV infection in humans is controversial (16). A paper published by MacNamara in 1954 described its isolation and exploited the possible association between ZIKV infection and jaundice (17). Another study, by Bearcroft in 1956, was on a volunteer that self-injected with the virus, who precisely described the symptoms following the infection (18). The only problem is that the virus isolated in the first study and used in the second one was not ZIKV but a Spondweni virus (SPOV) (16). MacNamara's study evaluated an epidemic of jaundice in Nigeria (Afikpo Division, Eastern Nigeria). From a study of three patients, the virus was isolated from a 10-year-old female patient who was not jaundiced but had symptoms of fever and headache, and her serological response to ZIKV was low (17).

Bearcroft's study was done to verify whether there was any association between ZIKV and the development of jaundice. A 34-year-old European male volunteer was exposed to the virus isolated by MacNamara (1956). Eighty-two hours post-infection (h.p.i.), the only symptom was a headache, followed by malaise and pyrexia in the 2nd and 3rd d.p.i. In the 5th d.p.i., there was a peak in the corporal temperature, accompanied by nausea and vertigo, which was diagnosed as histamine reaction. After 7 days, the volunteer had no sign of infection or jaundice. Mice infected with virus collected from the volunteer, in different periods, developed encephalitis after receiving sera collected at 4 and 6 d.p.i., which were around the peak of pyrexia. Meanwhile, the volunteer was exposed to *Aedes aegypti*, but the mosquitos were not able to transmit the infection to infant white mice (18).

The first clue that both studies were using SPOV was revealed in a study by Simpson (1964), which was also the first one to describe a natural infection of ZIKV in humans (19). In this paper he mentioned that previous isolations of ZIKV were made in Nigeria (West Africa), and Dr. Delphine Clarke had found out that those viruses were closely related to SPOV, which was named CHUKU strain. Another study in

1968 also pointed out that SPOV virus was isolated in Nigeria, and was wrongly identified as ZIKV (20). Simpson was actually the person who contracted the infection while working together with his team in Uganda. A detailed description of his symptoms following the natural infection was recorded. At the 1 d.p.i., he presented a headache, and by 2 d.p.i., he developed a red rash diffused throughout his face, neck, chest, and arms, without itching, and slight pain in the back and thighs. The rash covered all the limbs, including palms and soles. The fever started at 2 d.p.i., followed by malaise. At 3 d.p.i., the patient had no fever and did not feel sick, and at 5 d.p.i., there was no more rash (19). Actually, this was the first study that documented the presence of a rash on humans infected by ZIKV, one of the most common symptoms of ZIKV infection in today's patients (21).

The first isolation of ZIKV in Nigeria was reported in 1975 by Moore (1975) in a study describing the isolation of 15 arboviruses between 1964 and 1970 (22). Isolation of ZIKV in Oyo State, Nigeria, was described in 1979. The virus was isolated from two patients, a 2½-year-old boy with a mild fever in 1971, and a 10-year-old male in 1975, who presented with fever, headache, and pain in the body. This study suggested that ZIKV might be widespread, even if it had been isolated at a low rate. One important point mentioned in this study was that ZIKV infection numbers might be underestimated because of the mild symptoms or misdiagnosis with other arthropod-borne viral infections (23).

1.3 ZIKV Infection Spread to Other Hosts and Regions

Different serological studies were performed around the 1950s and 1960s and showed that the ZIKV infection had reached other areas in Africa and Asia (24, 25). Serological analysis, based on hemagglutination-inhibition (HI) tests of other animals, were described in 1977 with samples from 2,428 small mammals and 1,202 birds captured over a five-year period in Kano Plain, Kenya, close to Lake Victoria. The results revealed the prevalence of ZIKV antibodies as follows:

- In small mammals:
  - 4.0% (58/1,446) in *Arvicanthus niloticus*
  - 34.0% in (85/250) *Arvicanthis niloticus*
  - 3.1% (2/63) in *Crocidura occidentalis*

- In reptiles:
  - 40.0% (4/10) in *Boaedon fuliginosus*
  - 12.5% (1/8) in *Varanus niloticus*
- in birds:
  - 4.0% (2/49) in *Threskiornis aethiopicus*
  - 2.7% (1/37) in *Bubulcus ibis* and 50.0% (1/2) in *Philomachus pugnax*
- In other mammals:
  - 0.1% (1/655) in goats
  - 0.7% (2/283) in sheep
  - 0.6% (8/1361) in cattle living close to irrigated areas
  - 0.7% (7/963) in cattle from nonirrigated places (26)

Serological studies with human serum collected for the YFV research indicated that humans from some areas were exposed to ZIKV. There was no detection of ZIKV antibodies in the Zika and Kampala regions, while Bwamba had detection rates of ZIKV antibodies at 28.5% (2/7) in adults and 15.4% (2/13) in children, which were higher than the 9.5% (2/21) detection rate of West Nile antibodies in adults in this region (2). Dick (1952) was careful in his study and suggested that just because there was no evidence of an acute disease in humans caused by ZIKV infection, this did not indicate that ZIKV was not important or might not cause any problem in humans (2).

The detection of antibodies against ZIKV in South-East Asia was published in 1963, revealing that 75.0% (from 100 samples) of the population living in the Federation of Malayan (currently known as Peninsula of Malaya) was positive, while the presence of neutralization antibodies in the north region such as North Vietnam and Thailand (Bangkok and Chiang Mai) was rare (27). In 1965, ZIKV was detected in different regions of the Angola trough with 31.0% (40/129) and 1.5% (2/129) rates in children in the northwestern region by HI and neutralization tests, respectively, and with 57.7% (71/123) and 21.1% (26/123) rates in adults, respectively, by the same methods. In the southwestern region, 32.8% (20/61) and 21.3% (13/61) of the adults were positive by HI and neutralization tests, respectively, and for the eastern region, 3.5% (2/56) and 1.8% (1/56) of the adults were positive, also using HI and neutralization tests, respectively (28). Results from Kano Plain, Kenya, showed that ZIKV was endemic in 1973, but it was considered at a low level. By analyzing sera from children (ages 4–15+ years old) from schools distributed close to Lake Victoria,

ZIKV was detected by HI test in 7.2% (40/559) of the children grouped as 12 years old. Since this was considered a low rate, the other ages were not evaluated (29).

In 1974, a serological study to detect different arboviruses analyzed 1,649 human sera from Portugal and identified four (0.25%) individuals that reacted against ZIKV by the HI test, indicating the silent spread of the virus across the continents (30). In 1979, a serological study analyzed 235 samples from Hong Kong and detected 4.6% (11/235) ZIKV-positive individuals, which also cross-reacted with other flaviviruses. Among those who had gender and age information, 12.9% (4/31) females and 8.3% (1/12) males between 21 and 40 years old were positive, while 7.1% (1/14) males older than 41 years old were positive (31).

Interesting results were found at Kainji Lake Basin, Nigeria, in 1980, when ZIKV was detected by HI test, with cases concentrated in young adults and adults. Infection rate was correlated with increased age. Specifically, 9.3% (7/75) of 5- to 9-year-olds, 22.2% (8/36) of 10- to 14-year-olds, 46.1% (6/13) of 15- to 19-year-olds, 71.8% (61/85) of 20- to 39-year-olds, and 77.3% (68/88) of adults 40 years old and older (32) were positive. The continuous ZIKV detection by the HI test throughout Uganda villages in 1984 indicated that the incidence of ZIKV was not common in the region, with infection rates at 3.7% (1/27) in Tokora, 15.4% (2/13) in Nadip, 3.5% (2/58) in Namalu, and 20.0% (3/15) in other regions (33).

1.4   Cross-Paths between ZIKV and Other Flaviviruses

Analysis of sera collected from two different towns, Ilaro and Ilobi, in southwest Nigeria in 1951 and 1955 showed high detection rates of ZIKV antibodies in these populations. The distribution of ZIKV infection by age was as follows: 10.0% (3/29) among 5- to 9-year-olds, 22.0% (7/32) among 10- to 14-year-olds, 52.0% (13/25), among 15- to 19-year-olds, 76.0% (19/25) among 20- to 29-year-olds, 52.0% (16/31) among 30- to 39-year-olds, and 93.0% (28/30) for those adults 40 years old and older in Ilobi. In Ilaro, only children samples (4 to 16 years old) were collected, which showed a 44.0% positive rate for ZIKV antibodies. Besides ZIKV, high infection rates were also detected for DENV, YFV,

Uganda S virus (UGSV), and Bwamba fever virus (BWAV). There was association of antibodies against ZIKV, DENV, YFV, and UGSV, suggesting an overlapping protection. However, infection by one virus did not decrease the chance of being infected by another flavivirus, albeit it might reduce the pathogenesis. The most common combinations of infections were ZIKV or UGSV with YFV. Hence, a pre-infection with either ZIKV or UGSV might produce neutralization antibodies to YFV. ZIKV had a strong association with UGSV, YFV, and DENV. The DENV infection rate reached close to 100% in this region. It was suggested that ZIKV and UGSV might suppress YFV in the Forest Belt compared to other regions with high incidences of YFV and lower infection rates of ZIKV and UGSV (34).

The cyclic periodicity between ZIKV and chikungunya virus (CHIKV) was suggested by McCrae (1971) because there was no evidence that both viruses were maintained in the Entebbe region, but there were epizootic outbreaks with intervals of 5 to 8 and up to 10 years. The intervals were similar but not the same, with ZIKV following CHIKV outbreak after 1 to 2 years, which might be the result of the dynamic interactions of the viruses within the forest (35). In 1982, a study was published to address the possible interaction and interference in transmission between ZIKV and YFV. Mosquito's catches resulted in the isolation of 15 ZIKV strains from *Aedes africanus* and *Aedes apicoargenteus*. Dozens of monkeys were shot (after unsuccessful attempts of collecting blood) and captured to provide evidence of immunity change among the monkeys in the forest. Twenty-two Redtail monkeys were captured in Kisubi Forest while 68 monkeys (including Redtail, Mona, Colobus, and Mangabeys) were caught in Bwamba. After serological analysis, CHIKV was detected at high rates among the monkeys followed by ZIKV and YFV with similar rates, indicating that ZIKV infection did not prevent the circulation of YFV (36).

References

1 Dick GW, Kitchen SF, Haddow AJ. 1952. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg **46**:509–520.
2 Dick GW. 1952. Zika virus. II. Pathogenicity and physical properties. Trans R Soc Trop Med Hyg **46**:521–534.

3 Haddow AJ, Dick GW, Lumsden WH, Smithburn KC. 1951. Monkeys in relation to the epidemiology of yellow fever in Uganda. Trans R Soc Trop Med Hyg **45**:189–224.

4 Findlay GM, Maccallum FO. 1937. Yellow fever immune bodies in the blood of African primates. Transactions of the Royal Society of Tropical Medicine and Hygiene **31**:103–106.

5 Maccallum FO, Findlay GM. 1937. Yellow fever immune bodies and animal sera. Transactions of the Royal Society of Tropical Medicine and Hygiene **31**:199–206.

6 Haddow AJ, Smithburn KC, et al. 1947. Monkeys in relation to yellow fever in Bwamba County, Uganda. Trans R Soc Trop Med Hyg **40**:677–700.

7 Smithburn KC, Kerr JA, Gatne PB. 1954. Neutralizing antibodies against certain viruses in the sera of residents of India. J Immunol **72**:248–257.

8 Smithburn KC. 1954. Neutralizing antibodies against arthropod-borne viruses in the sera of long-time residents of Malaya and Borneo. Am J Hyg **59**:157–163.

9 Hammon WM, Schrack WD, Jr., Sather GE. 1958. Serological survey for a arthropod-borne virus infections in the Philippines. Am J Trop Med Hyg **7**:323–328.

10 Theiler M. 1934. Spontaneous Encephalomyelitis of Mice–a New Virus Disease. Science **80**:122.

11 Theiler M. 1937. Spontaneous Encephalomyelitis of Mice, a New Virus Disease. J Exp Med **65**:705–719.

12 Haddow AJ, Williams MC, Woodall JP, Simpson DI, Goma LK. 1964. Twelve Isolations of Zika Virus from Aedes (Stegomyia) Africanus (Theobald) Taken in and above a Uganda Forest. Bull World Health Organ **31**:57–69.

13 Dick GW. 1953. Epidemiological notes on some viruses isolated in Uganda; Yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda S and Zika viruses. Trans R Soc Trop Med Hyg **47**:13–48.

14 Weinbren MP, Williams MC. 1958. Zika virus: further isolations in the Zika area, and some studies on the strains isolated. Trans R Soc Trop Med Hyg **52**:263–268.

15 Lee VH, Moore DL. 1972. Vectors of the 1969 yellow fever epidemic on the Jos Plateau, Nigeria. Bull World Health Organ **46**:669–673.

16 Wikan N, Smith DR. 2017. First published report of Zika virus infection in people: Simpson, not MacNamara. Lancet Infect Dis **17**:15–17.

17 Macnamara FN. 1954. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans R Soc Trop Med Hyg **48**:139–145.

18 Bearcroft WG. 1956. Zika virus infection experimentally induced in a human volunteer. Trans R Soc Trop Med Hyg **50**:442–448.

19 Simpson DI. 1964. Zika Virus Infection in Man. Trans R Soc Trop Med Hyg **58**:335–338.

20 Boorman JP, Draper CC. 1968. Isolations of arboviruses in the Lagos area of Nigeria, and a survey of antibodies to them in man and animals. Trans R Soc Trop Med Hyg **62**:269–277.

21 Musso D, Gubler DJ. 2016. Zika Virus. Clin Microbiol Rev **29**:487–524.

22 Moore DL, Causey OR, Carey DE, Reddy S, Cooke AR, Akinkugbe FM, David-West TS, Kemp GE. 1975. Arthropod-borne viral infections of man in Nigeria, 1964–1970. Ann Trop Med Parasitol **69**:49–64.

23 Fagbami AH. 1979. Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State. J Hyg (Lond) **83**:213–219.

24 Smithburn KC, Taylor RM, Rizk F, Kader A. 1954. Immunity to certain arthropod-borne viruses among indigenous residents of Egypt. Am J Trop Med Hyg **3**:9–18.

25 Smithburn KC. 1952. Neutralizing antibodies against certain recently isolated viruses in the sera of human beings residing in East Africa. J Immunol **69**:223–234.

26 Johnson BK, Chanas AC, Shockley P, Squires EJ, Gardner P, Wallace C, Simpson DI, Bowen ET, Platt GS, Way H, Parsons J, Grainger WE. 1977. Arbovirus isolations from, and serological studies on, wild and domestic vertebrates from Kano Plain, Kenya. Trans R Soc Trop Med Hyg **71**:512–517.

27 Pond WL. 1963. Arthropod-Borne Virus Antibodies in Sera from Residents of South-East Asia. Trans R Soc Trop Med Hyg **57**:364–371.

28 Kokernot RH, Casaca VM, Weinbren MP, McIntosh BM. 1965. Survey for antibodies against arthropod-borne viruses in the sera of indigenous residents of Angola. Trans R Soc Trop Med Hyg **59**:563–570.

29 Bowen ET, Simpson DI, Platt GS, Way H, Bright WF, Day J, Achapa S, Roberts JM. 1973. Large scale irrigation and arbovirus epidemiology, Kano Plain, Kenya. II. Preliminary serological survey. Trans R Soc Trop Med Hyg **67**:702–709.

30 Filipe AR. 1974. Serological survey for antibodies to arboviruses in the human population of Portugal. Trans R Soc Trop Med Hyg **68**:311–314.

31 Johnson BK, Chanas AC, Gardner P, Simpson DI, Shortridge KF. 1979. Arbovirus antibodies in the human population of Hong Kong. Trans R Soc Trop Med Hyg **73**:594–596.

32 Adekolu-John EO, Fagbami AH. 1983. Arthropod-borne virus antibodies in sera of residents of Kainji Lake Basin, Nigeria 1980. Trans R Soc Trop Med Hyg **77**:149–151.

33 Rodhain F, Gonzalez JP, Mercier E, Helynck B, Larouze B, Hannoun C. 1989. Arbovirus infections and viral haemorrhagic fevers in Uganda: a serological survey in Karamoja district, 1984. Trans R Soc Trop Med Hyg **83**:851–854.

34 Macnamara FN, Horn DW, Porterfield JS. 1959. Yellow fever and other arthropod-borne viruses; a consideration of two serological surveys made in South Western Nigeria. Trans R Soc Trop Med Hyg **53**:202–212.

35 McCrae AW, Henderson BE, Kirya BG, Sempala SD. 1971. Chikungunya virus in the Entebbe area of Uganda: isolations and epidemiology. Trans R Soc Trop Med Hyg **65**:152–168.

36 McCrae AW, Kirya BG. 1982. Yellow fever and Zika virus epizootics and enzootics in Uganda. Trans R Soc Trop Med Hyg **76**:552–562.